Medivir AB (MVRBF) Release: Interim Results (SVR4) From A Phase 2 All-Oral Combination Study Of Simeprevir And Samatasvir (IDX719) For The Treatment Of Hepatitis C
1/13/2014 9:46:34 AM
Stockholm, Sweden—Medivir AB (OMX: MVIR), announces that Idenix Pharmaceuticals,
Inc. today released interim data from the ongoing phase II HELIX-1 clinical
trial evaluating an all-oral, direct-acting antiviral (DAA) HCV combination
regimen of samatasvir (IDX719), Idenix’s once-daily pan-genotypic NS5A
inhibitor, and simeprevir , a once-daily protease inhibitor jointly developed by
Janssen R&D Ireland and Medivir AB, and ribavirin.
Help employers find you! Check out all the jobs and post your resume.
comments powered by